α-PD-1 therapy elevates Treg/Th balance and increases tumor cell pSmad3 that are both targeted by α-TGFβ antibody to promote durable rejection and immunity in squamous cell carcinomas

[1]  P. Iversen,et al.  Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade , 2018, Journal of Immunotherapy for Cancer.

[2]  J. Bluestone,et al.  Targeting EZH2 Reprograms Intratumoral Regulatory T Cells to Enhance Cancer Immunity , 2018, Cell reports.

[3]  Camille Stephan-Otto Attolini,et al.  TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis , 2018, Nature.

[4]  R. Bourgon,et al.  TGF-β attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells , 2018, Nature.

[5]  V. Servois,et al.  Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  Daniel M. Corey,et al.  PD-1 expression by tumor-associated macrophages inhibits phagocytosis and tumor immunity , 2017, Nature.

[7]  A. Quaas,et al.  Characterization of tumor-associated T-lymphocyte subsets and immune checkpoint molecules in head and neck squamous cell carcinoma , 2017, Oncotarget.

[8]  Nicolai J. Birkbak,et al.  Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors , 2017, Immunity.

[9]  J. Berzofsky,et al.  Blockade of only TGF-β 1 and 2 is sufficient to enhance the efficacy of vaccine and PD-1 checkpoint blockade immunotherapy , 2017, Oncoimmunology.

[10]  Razelle Kurzrock,et al.  Hyperprogressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate , 2017, Clinical Cancer Research.

[11]  R. Ferris,et al.  Adaptive resistance to anti-PD1 therapy by Tim-3 upregulation is mediated by the PI3K-Akt pathway in head and neck cancer , 2017, Oncoimmunology.

[12]  D. Pardoll,et al.  TGFβ1-Mediated SMAD3 Enhances PD-1 Expression on Antigen-Specific T Cells in Cancer. , 2016, Cancer discovery.

[13]  Charles Ferté,et al.  Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1 , 2016, Clinical Cancer Research.

[14]  L. Nardo,et al.  Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma. , 2016, The Journal of clinical investigation.

[15]  J. Wolchok,et al.  Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma. , 2016, JAMA.

[16]  J. Sosman,et al.  Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma , 2016, Cell.

[17]  J. Gartner,et al.  Immunogenicity of somatic mutations in human gastrointestinal cancers , 2015, Science.

[18]  Shireen Khan,et al.  Development and characterization of human monoclonal antibodies that neutralize multiple TGFβ isoforms , 2015, mAbs.

[19]  A. Balmain,et al.  Evolution of metastasis revealed by mutational landscapes of chemically induced skin cancers , 2015, Nature Medicine.

[20]  D. Chaussabel,et al.  The Relationship of Immune Cell Signatures to Patient Survival Varies within and between Tumor Types , 2015, PloS one.

[21]  D. Barouch,et al.  CD4 T Cell Depletion Substantially Augments the Rescue Potential of PD-L1 Blockade for Deeply Exhausted CD8 T Cells , 2015, The Journal of Immunology.

[22]  H. Fan,et al.  Upregulation of PD-1 on CD4⁺CD25⁺ T cells is associated with immunosuppression in liver of mice infected with Echinococcus multilocularis. , 2015, International immunopharmacology.

[23]  J. Zavadil,et al.  TGFβ Is a Master Regulator of Radiation Therapy-Induced Antitumor Immunity. , 2015, Cancer research.

[24]  T. Schumacher,et al.  Neoantigens in cancer immunotherapy , 2015, Science.

[25]  Martin L. Miller,et al.  Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer , 2015, Science.

[26]  Sebastian Amigorena,et al.  Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity. , 2014, Cancer cell.

[27]  Marie M. Lee,et al.  Genetic variants of Adam17 differentially regulate TGFβ signaling to modify vascular pathology in mice and humans , 2014, Proceedings of the National Academy of Sciences.

[28]  David T. W. Jones,et al.  Signatures of mutational processes in human cancer , 2013, Nature.

[29]  R. Schreiber,et al.  Cancer immunoediting: antigens, mechanisms, and implications to cancer immunotherapy , 2013, Annals of the New York Academy of Sciences.

[30]  A. Hata,et al.  Targeting the TGFβ signalling pathway in disease , 2012, Nature Reviews Drug Discovery.

[31]  Ming O. Li,et al.  Tgf-β1 produced by activated CD4+ T Cells Antagonizes T Cell Surveillance of Tumor Development , 2012, Oncoimmunology.

[32]  S. Mukhopadhyay,et al.  Preferential expression of integrin αvβ8 promotes generation of regulatory T cells by mouse CD103+ dendritic cells. , 2011, Gastroenterology.

[33]  J. Allison,et al.  T cell surveillance of oncogene-induced prostate cancer is impeded by T cell-derived TGF-β1 cytokine. , 2011, Immunity.

[34]  Hao Zhang,et al.  Abstract 1: Mcl-1 downregulation plays a crucial role in the synergistic anticancer activities between PI-3 kinase inhibitors and histone deacetylase inhibitors in primary NSCLC tumorsin vitroandin vivo , 2011 .

[35]  B. Hann,et al.  Outgrowth of drug-resistant carcinomas expressing markers of tumor aggression after long-term TβRI/II kinase inhibition with LY2109761. , 2011, Cancer research.

[36]  Richard A. Flavell,et al.  The polarization of immune cells in the tumour environment by TGFβ , 2010, Nature Reviews Immunology.

[37]  P. Rod Dunbar,et al.  Human CD141+ (BDCA-3)+ dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens , 2010, The Journal of experimental medicine.

[38]  J. Allison,et al.  PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors , 2010, Proceedings of the National Academy of Sciences.

[39]  S. Liyanarachchi,et al.  Germline Allele-Specific Expression of TGFBR1 Confers an Increased Risk of Colorectal Cancer , 2008, Science.

[40]  Chen Dong,et al.  Molecular antagonism and plasticity of regulatory and inflammatory T cell programs. , 2008, Immunity.

[41]  A. Chang,et al.  Tumor-induced immune suppression of in vivo effector T-cell priming is mediated by the B7-H1/PD-1 axis and transforming growth factor beta. , 2008, Cancer research.

[42]  K. Furuuchi,et al.  Smad3 and NFAT cooperate to induce Foxp3 expression through its enhancer , 2008, Nature Immunology.

[43]  대니얼 베딩거,et al.  Prlr-specific antibody and uses thereof , 2007 .

[44]  N. Darwiche,et al.  The high‐risk benign tumor: Evidence from the two‐stage skin cancer model and relevance for human cancer , 2007, Molecular carcinogenesis.

[45]  A. Balmain,et al.  Genetic variants of Tgfb1 act as context-dependent modifiers of mouse skin tumor susceptibility. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[46]  A. Balmain,et al.  Metastasis is driven by sequential elevation of H-ras and Smad2 levels , 2002, Nature Cell Biology.

[47]  T. Jacks,et al.  Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. , 2001, Genes & development.

[48]  A. Balmain,et al.  Transforming growth factor beta is essential for spindle cell conversion of mouse skin carcinoma in vivo: implications for tumor invasion. , 1998, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[49]  Allan Balmain,et al.  TGFβ1 Inhibits the Formation of Benign Skin Tumors, but Enhances Progression to Invasive Spindle Carcinomas in Transgenic Mice , 1996, Cell.

[50]  R. Akhurst,et al.  Localized production of TGF-β mRNA in tumour promoter-stimulated mouse epidermis , 1988, Nature.

[51]  A. Nebreda,et al.  TGF ‐ beta drives immune evasion in genetically reconstituted colon cancer metastasis , 2018 .

[52]  Sebastian Amigorena,et al.  Dissecting the Tumor Myeloid Compartment Reveals Rare Activating Antigen-Presenting Cells Critical for T Cell Immunity. , 2014, Cancer cell.

[53]  A. Balmain,et al.  Localized production of TGF-beta mRNA in tumour promoter-stimulated mouse epidermis. , 1988, Nature.